Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509079 | 0.97 | ALDH1A1 (0.47) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL566326 | 0.97 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL175198 | 0.94 | — | — | |
| SCHEMBL674177 | 0.91 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL567977 | 0.88 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL674050 | 0.86 | CXCR4 (0.53) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL10036 | 0.85 | — | — | |
| SCHEMBL1782168 | 0.85 | CXCR4 (0.41) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL1782381 | 0.82 | HIF1A (0.50) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL567629 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095031-B1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2013-08-21 | — | — | EP | claimed |
| US-20040235814-A1 | Methods to treat conditions mediated by chemokine receptors | GENZYME CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-6756391-B2 | CYCLIC POLYAMINES HAVING TOTAL 9-24 MEMBERS WHICH HAVE ACTIVITY IN AGAINST HIV-INFECTED CELLS AS WELL AS OTHER BIOLOGICAL ACTIVITY RELATED TO BINDING OF LIGANDS TO CHEMOKINE RECEPTORS | ANORMED, INC. (CA) | 2004-06-29 | — | — | US | claimed |
| US-20030018189-A1 | Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors | GENZYME CORPORATION | 2003-01-23 | — | — | US | claimed |
| EP-1095031-B1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20110280827-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | HU YANPING (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281814-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | GENZYME CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | GENZYME CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2010025416-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | GENZYME CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| EP-2056853-A1 | COMBINATION THERAPY | Genzyme Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008019371-A1 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20070043012-A1 | Methods to enhance chemotherapy | GENZYME CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | ANORMED INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | CXCR4, CXCR3, CXCR1 | ALDH1A1 1474/4885CXCR4 1/4885SMN1; SMN2 4338/4885 |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | CXCL12, CXCR2, CXCR4 | ALDH1A1 328/4885CXCR4 3/4885SMN1; SMN2 1674/4885 |
| US-20070043012-A1 | Methods to enhance chemotherapy | CXCR4, MCL1, CXCL12 | ALDH1A1 2257/4885CXCR4 1/4885SMN1; SMN2 2127/4885 |
| US-20100178271-A1 | Combination Therapy | CXCL12, CSF3R, CXCR4 | ALDH1A1 1587/4885CXCR4 3/4885SMN1; SMN2 2474/4885 |
| US-20100003224-A1 | Combination Therapy | CXCL12, CXCR4, SDF4 | ALDH1A1 703/4885CXCR4 2/4885SMN1; SMN2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.